News
Description of a Hospital Unit
Description of a Hospital Unit
Our hospital is a modern research center that combines the capacity of a nearly 300-bed medical facility with the expertise of a qualified team and comprehensive diagnostic capabilities. We ensure that sponsors and CROs can conduct clinical trials efficiently, in accordance with the highest quality and safety standards.
Our strengths include one of the most advanced Laboratory Diagnostics Centers in Lower Silesia, a state-of-the-art Imaging Diagnostics Center available 24 hours a day (X-ray, CT, MRI), and a hospital pharmacy that conducts all procedures in accordance with Good Clinical Practice guidelines (ICH GCP E6). As a result, we are able to provide comprehensive support for medical tests at every stage of the process.
We fully understand how critical the project start date is. That is why we guarantee a fast and reliable feasibility process, based on a detailed analysis of patient databases. Once the research protocol is approved, we ensure the contracting process runs smoothly and provide professional support during the study launch phase. A dedicated start-up team oversees this process, ensuring that all activities are carried out efficiently and on time.
Our strength lies in our team of experienced medical specialists representing many fields of medicine. Researchers conduct clinical trials while also working in hospital wards and specialty clinics, which ensures constant access to relevant patient populations and effective recruitment.
We conduct Phase II, III, and IV clinical trials in a number of therapeutic areas, including:
- nephrology,
- neurology,
- infectious diseases,
- metabolic diseases,
- musculoskeletal disorders,
- preventive vaccinations,
- and other specialties developed in collaboration with Sponsors.
We are continuously expanding our research capabilities, broadening the scope of clinical trials conducted across both our inpatient hospital wards and outpatient clinics. We are open to new projects and long-term partnerships with Sponsors and Contract Research Organizations (CROs), offering professional support, flexibility, and the highest standard of clinical trial execution.
Equally important to us is patient education. We aim to ensure that as many patients as possible understand the opportunities, benefits, and principles of participating in clinical trials, enabling them to make informed decisions about their treatment. We encourage you to explore the educational materials prepared by the Medical Research Agency (ABM) on the website https://pacjentwbadaniach.abm.gov.pl/, which clearly explains the nature of clinical trials, what participation involves, and the rights and responsibilities of trial participants.
We look forward to collaborating with you.
To discuss clinical trial opportunities, please contact:
Alicja Hetnar, M.Sc. Eng.
Head of the Clinical Research and Translational Medicine Support Center /
Clinical Research Coordinator Tel.: +48 661 426 767
E-mail: badaniakliniczne@szpitalboleslawiec.pl
E-mail: ahetnar@szpitalboleslawiec.pl
| Status | Study Title | EudraCT Number / Study Protocol Number | Indication | Principal Investigator |
| Active | A multinational, multicenter, double-blind study evaluating the efficacy and safety of bovine chondroitin sulfate 800 mg tablets compared to marine chondroitin sulfate 800 mg tablets in the treatment of pain and functional impairment in knee osteoarthritis | 2024-516337-12-00/ 23EU-Ct11 | Knee Osteoarthritis | Mirosław Kulej, MD, PhD |
| Active | An international, observational secondary data-based study describing management and dapagliflozin treatment in routine practice in patients with chronic kidney disease in Central and Eastern Europe. | D169AR00025 | Chronic Kidney Disease | Prof. Mariusz Kusztal, MD, PhD |
| Closed | A single-arm, open-label Phase III study evaluating the safety and tolerability of intra-articular injections of RTX-GRT7039 in patients with moderate to severe osteoarthritis knee pain | 2021-005046-15/ KF7039-03 | Moderate to severe osteoarthritis knee pain | Mirosław Kulej, MD, PhD |
| Closed | A multicenter, randomized, double-blind, active-controlled Phase 3 study to evaluate the efficacy and safety of cefepime-zidebactam compared with meropenem in the treatment of complicated urinary tract infection or acute pyelonephritis in adults | 2019-002768-28 / W-5222-301 | Complicated urinary tract infection or acute pyelonephritis in adults | Artur Nahorecki, MD |
| Closed | A multicenter, randomized, placebo-controlled, observer-blind Phase 3 study to evaluate the efficacy, safety, tolerability, immunogenicity, and lot consistency of a 6-valent OspA-based Lyme disease vaccine in healthy participants aged > 5 years. | 2021-005427-20 / C4601003 | Lyme disease prophylaxis | Aleksandra Kopczyńska, MD |
| Closed | A randomized, double-blind, parallel-group, placebo-controlled Phase III study to demonstrate the efficacy and safety of milvexian, an oral factor XIa inhibitor, after acute ischemic stroke or high-risk transient ischemic attack. | 2022-501176-26-00 / 70033093STR3001 | Secondary prevention of ischemic stroke / TIA | Justyna Straszak-Trzeciak, MD |
| Closed | A multicenter, randomized, double-blind Phase 3 study to evaluate the safety and efficacy of contezolid acefosamil and contezolid compared with linezolid in intravenous and oral therapy in adults with moderate to severe diabetic foot infections | 2022-500257-16 / MRXC-302 | Moderate to severe diabetic foot infections | Wojciech Hap, MD, PhD |
| Closed | A multicenter, randomized, double-blind, placebo-controlled Phase III trial to evaluate the efficacy of Asunercept in the treatment of hospitalized patients with moderate to severe COVID-19 | 2021-006005-30 / APG101_CD_018 | COVID-19 | Artur Nahorecki, MD |
| Closed | A randomized, double-blind, placebo-controlled, 3-part pilot study to evaluate the tolerability, safety, and pharmacokinetics of DFT patch in healthy adults. | DFT-01-2020 | Overweight | Artur Nahorecki, MD |
| Closed | A randomized, open-label, adaptive, parallel-group, Phase IIb/III trial to assess the efficacy and safety of intravenous alteplase administered daily for up to 5 days plus standard of care compared with standard of care alone in subjects with acute respiratory distress syndrome due to COVID-19 infection | 2020-002913-16 / 0135-0347 | COVID-19 | Justyna Straszak-Trzeciak, MD |
| Closed | RESPIRE – A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the safety and efficacy of ATR-002 in hospitalized adult patients with COVID-19 | 2020-004206-59/ ATR-002-202 | COVID-19 | Jarosław Ciaś, MD |
| Closed | RESPIRE – A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the safety and efficacy of ATR-002 in hospitalized adult patients with COVID-19 | 2020-004206-59/ ATR-002-202 | COVID-19 | Artur Nahorecki, MD |
| Closed | A multicenter, randomized, double-blind, placebo-controlled, prospective trial on the efficacy and safety of amantadine in hospitalized patients with early-stage moderate to severe COVID-19. | 2021/ABM/COVID19/GCM/ TITAN | COVID-19 | Artur Nahorecki, MD |
| Closed | A randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of EB05 in combination with standard of care vs placebo in combination with standard of care in hospitalized adult patients with COVID-19 | EB05-04-2020 | COVID-19 | Artur Nahorecki, MD |
| Closed | Opaganib, a sphingosine kinase-2 (SK2) inhibitor in COVID-19 pneumonia: a randomized, double-blind, placebo-controlled Phase 2/3 study in hospitalized adult patients with severe SARS-CoV-2 pneumonia | ABC-201 | COVID-19 | Ewelina Nahorecka, MD |
| Closed | A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of estetrol (E4) in the treatment of patients with confirmed SARS-CoV-2 infection | 2020-003403-33/ MIT-Co001-C101 | COVID-19 | Justyna Straszak-Trzeciak, MD |